Novartis AG ADR (NVS)vsNyxoah (NYXH)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
NYXH
Nyxoah
$2.95
+0.68%
HEALTHCARE · Cap: $130.99M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 564551% more annual revenue ($56.58B vs $10.02M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
NYXH
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Intrinsic value data unavailable for NYXH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Revenue surging 346.9% year-over-year
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : NYXH
The strongest argument for NYXH centers on Revenue Growth, Price/Book. Revenue growth of 346.9% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : NYXH
The primary concerns for NYXH are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a declining stock while NYXH is a hypergrowth play — different risk/reward profiles.
NYXH carries more volatility with a beta of 0.87 — expect wider price swings.
NYXH is growing revenue faster at 346.9% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 29/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Nyxoah
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Nyxoah is a leading medical technology company focused on revolutionizing the treatment of obstructive sleep apnea (OSA) through its groundbreaking Genio system, which utilizes minimally invasive hypoglossal nerve stimulation techniques. With a strong commitment to clinical validation and ongoing research, Nyxoah aims to significantly improve patient outcomes and overall quality of life for individuals suffering from OSA. The company's strategic focus on innovation and technology, enhanced by robust partnerships and comprehensive studies, positions it well to capitalize on unmet needs within the sleep medicine market, highlighting its potential for sustainable growth and impactful contributions to the healthcare landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?